F. Cock

发表

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993 .

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration

M. Verstraete, D. Collen, J. Schetz, 1977, European journal of clinical investigation.

Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro

O. Matsuo, D. Collen, H. Lijnen, 1992 .

Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase

P. Declerck, H. Lijnen, D. Collen, 1992 .

Isolation and conditioning of recombinant staphylokinase for use in man

D. Collen, M. Mol, J. Stassen, 1993 .

Thrombin-Antithrombin III and Plasm in-Antiplasmin Complexes as Indicators of in Vivo Activation of the Coagulation and/or Fibrinolytic Systems

D. Collen, F. Cock, 1977, Thrombosis and Haemostasis.

Quantitation of thrombin‐antithrombin III complexes in human blood

M. Verstraete, D. Collen, F. Cock, 1977, European journal of clinical investigation.

A latex agglutination test for rapid quantitative estimation of the plasmin–antiplasmin complex in human plasma

D. Collen, P. Masson, F. Cock, 1977, European journal of clinical investigation.

Characterisation of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site

L. Nelles, D. Collen, H. Lijnen, 1992 .

Biochemical and Biological Properties of a Recombinant Tissue-Type Plasminogen Activator Derived from the Rat JMI-229 Cell Line

D. Collen, H. Lijnen, B. van Hoef, 1992, Thrombosis and Haemostasis.

Double-blind randomized study of oral Fluconazole versus Ketoconazole in 40 episodes of oropharyngeal cadidiasis in ARC/AIDS patients

N. Clumeck, D. Weerts, S. Wit, 1989 .

Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin

M. Dewerchin, D. Collen, H. Lijnen, 1990 .

Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.

D. Collen, D. Rijken, I. Juhan-vague, 1983, The Journal of laboratory and clinical medicine.

Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.

D. Collen, I. Juhan-vague, M. Aillaud, 1984, Thrombosis research.

Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.

D. Collen, F. J. Van de Werf, H. Bounameaux, 1985, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.

G. Matthyssens, P. Holvoet, D. Collen, 1993, Blood.

Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase

A. Vandamme, M. Dewerchin, P. Holvoet, 1992, Thrombosis and Haemostasis.